查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602796

肥胖药物市场：依治疗类型、最终用途划分 - 2025-2030 年全球预测

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肥胖药物市场规模为99.8亿美元，预计2024年将达108.1亿美元，复合年增长率为8.44%，2030年将达176亿美元。

肥胖药物市场涵盖治疗肥胖及相关疾病的药物和治疗方法的开拓、生产和销售。该行业的定义是，日益增长的对抗全球肥胖流行病的需求是由肥胖率上升以及糖尿病、心血管疾病和某些癌症等相关健康併发症引起的。人们对肥胖对健康影响的认识不断提高、医疗保健成本增加以及针对体重管理的公共卫生努力推动了对肥胖药物的需求。其应用包括药品、营养食品和生活方式干预，最终用户范围从医疗保健提供者和健身中心到寻求减重解决方案的个人消费者。影响该市场的主要成长要素包括药物开发的技术进步、政府对医疗保健创新的奖励以及不断增加的研发投资。此外，生物技术的进步和消费者对体重管理药物干预措施的接受程度不断提高也推动了市场的发展。

主要市场统计
基准年[2023] 99.8亿美元
预测年份 [2024] 108.1亿美元
预测年份 [2030] 176亿美元
复合年增长率（%） 8.44%

全球肥胖症盛行率不断上升，以及对更有效、更安全的治疗方法日益增长的需求，创造了潜在的商机。公司可以透过开发针对特定基因谱的新型疗法和个人化医疗方法来利用这些机会。然而，它们面临着严格的监管要求、高昂的研发成本以及与抗肥胖药物相关的潜在副作用等限制和挑战，阻碍了它们的更广泛采用。创新领域包括探索具有体重管理作用的天然成分、研究肠道微生物组在肥胖中的作用，以及推广联合治疗以提高疗效并减少副作用。随着市场的发展，公司扩展到正在经历人口和生活方式变化而导致肥胖率增加的新兴市场是有利的。在这种竞争格局中，与研究机构和医疗保健提供者的合作和伙伴关係对于克服挑战和促进创新至关重要。了解市场趋势和消费行为使公司能够有效地驾驭这个动态空间。

市场动态：揭示快速发展的肥胖药物市场的关键市场洞察

供需的动态交互作用正在改变肥胖药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 肥胖及相关疾病增加
    • 由于缺乏运动而导致久坐的生活方式增加
    • 新型抗肥胖药物介绍
  • 市场限制因素
    • 肥胖药物副作用的风险，包括精神疾病和中风
  • 市场机会
    • 正在进行的临床试验和研发活动
    • 与临床显着体重减轻相关的药物标靶增加
  • 市场挑战
    • 缺乏体重管理知识

波特的五力：驾驭肥胖药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肥胖药物市场的外部影响

外部宏观环境因素在塑造肥胖药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肥胖治疗药物市场的竞争状况

对肥胖药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 减重药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估减重药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划肥胖药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对肥胖药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肥胖及相关疾病的发生率增加
      • 由于缺乏运动而导致久坐的生活方式增加
      • 新型抗肥胖药物介绍
    • 抑制因素
      • 肥胖药物副作用的风险，例如精神障碍和中风
    • 机会
      • 正在进行的临床试验和研发活动
      • 与临床显着体重减轻相关的药物标靶增加
    • 任务
      • 体重管理知识有限
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的肥胖治疗药物市场

  • 药品
    • 安非他酮-纳曲酮
    • Liraglutide
    • 奥利司他
    • 芬特明-托吡酯
    • Semaglutide
  • 治疗
    • 可调式胃束带
    • 内视镜袖状胃成形术
    • 胃绕道手术

第七章肥胖药物市场：依最终用途

  • 门诊手术中心
  • 医院
  • 专科诊所

第八章北美和南美肥胖药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肥胖药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲肥胖药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Norgine BV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus LLC
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market was valued at USD 9.98 billion in 2023, expected to reach USD 10.81 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 17.60 billion by 2030.

The scope of the anti-obesity therapeutics market involves developing, producing, and marketing drugs and treatments that address obesity and related conditions. This industry is defined by a growing need to combat the global obesity epidemic, driven by rising obesity rates and associated health complications such as diabetes, cardiovascular diseases, and certain cancers. The necessity for anti-obesity therapeutics stems from heightened awareness of obesity's health effects, increased healthcare costs, and public health initiatives targeting weight management. Its application includes pharmaceuticals, dietary supplements, and lifestyle interventions, with end-users ranging from healthcare providers and fitness centers to individual consumers seeking weight loss solutions. Key growth factors influencing this market include technological advancements in drug development, government incentives for healthcare innovation, and increased investment in research and development. Additionally, the market is buoyed by a surge in biotechnology advancements and growing consumer acceptance of pharmaceutical interventions for weight management.

KEY MARKET STATISTICS
Base Year [2023] USD 9.98 billion
Estimated Year [2024] USD 10.81 billion
Forecast Year [2030] USD 17.60 billion
CAGR (%) 8.44%

Potential opportunities arise from the increasing prevalence of obesity worldwide, driving demand for more effective and safer treatments. Companies can capitalize on these opportunities by developing novel therapeutics and personalized medicine approaches tailored to specific genetic profiles. However, the market faces limitations and challenges, such as stringent regulatory requirements, high R&D costs, and potential side effects associated with anti-obesity drugs, which hinder broader adoption. Innovation areas include exploring natural ingredients with weight management benefits, investigating the role of gut microbiome in obesity, and advancing combination therapies to enhance efficacy and reduce side effects. As the market evolves, businesses can benefit from expanding into emerging markets experiencing demographic and lifestyle changes driving obesity rates. In this competitive landscape, collaborations and partnerships with research institutions and healthcare providers are crucial to overcoming challenges and fostering innovation. Insights into market trends and consumer behavior will enable companies to navigate this dynamic sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Therapeutics Market

The Anti-Obesity Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of obesity and related disorder
    • Rising adoption of sedentary lifestyle due to lack of exercise
    • Introduction of novel anti-obesity drugs
  • Market Restraints
    • Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
  • Market Opportunities
    • Ongoing clinical trials and research & development activities
    • Increasing number of drug targets associated with clinically significant weight loss
  • Market Challenges
    • Limited of knowledge regarding weight management

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Therapeutics Market

A detailed market share analysis in the Anti-Obesity Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Therapeutics Market

A strategic analysis of the Anti-Obesity Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, and Semaglutide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.
  • Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
    • 5.1.4. Challenges
      • 5.1.4.1. Limited of knowledge regarding weight management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bupropion-naltrexone
    • 6.2.2. Liraglutide
    • 6.2.3. Orlistat
    • 6.2.4. Phentermine-topiramate
    • 6.2.5. Semaglutide
  • 6.3. Treatments
    • 6.3.1. Adjustable Gastric Banding
    • 6.3.2. Endoscopic Sleeve Gastroplasty
    • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Boehringer Ingelheim International GmbH
  • 2. Bristol-Myers Squibb Company
  • 3. Currax Pharmaceuticals LLC
  • 4. Eisai Co., Ltd.
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co., Inc.
  • 9. Norgine B.V.
  • 10. Novartis AG
  • 11. Novo Nordisk A/S
  • 12. Pfizer Inc.
  • 13. Rhythm Pharmaceuticals, Inc.
  • 14. SHIONOGI & Co., Ltd.
  • 15. Takeda Pharmaceutical Company Limited
  • 16. Vivus LLC

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023